| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66467fe5b0acf469afb972f300bcfb87 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1273
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2015-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab16134e8ffc5e3255f26413a800889f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2663090bc354d62bfe3ca4c49de9209e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1381d86c146b9b63aaa6a02e31ed342d |
| publicationDate |
2020-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2737723-T3 |
| titleOfInvention |
Compositions comprising IL-31 and uses thereof |
| abstract |
IL-31 or peptide that is at least about 70% homologous to the sequence of IL-31 as set forth in SEQ ID NO. 1, a fusion protein comprising IL-31 or peptide that is at least about 70% homologous to the IL-31 sequence as set forth in SEQ ID NO. 1, or a complex comprising IL-31 or peptide that is at least about 70% homologous to the IL-31 sequence as set forth in SEQ ID NO. 1 or a fusion protein comprising IL-31 or peptide that is at least about 70% homologous to the IL-31 sequence as set forth in SEQ ID NO. 1 for use in the treatment of cancer that expresses an IL-31 receptor. |
| priorityDate |
2014-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |